Afshan Mccarthy
Molecular Biology · 2009–2010
A researcher in the Science corpus: 2 papers; trusts 3 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Molecular Biology — 20 citations into it
- Oncology — 20 citations into it
Whom Afshan Mccarthy trusts
Their strongest outbound trust, strongest first, inferred from their citations.
- Alan Ashworth (in Molecular Biology)
- W. Kaelin (in Molecular Biology)
- S. West (in Molecular Biology)
Papers from Afshan Mccarthy's perspective
Ordered by how strongly the researchers Afshan Mccarthy trusts endorse each paper. Same corpus, a different order for every researcher.
- Diagnosis of multiple cancer types by shrunken centroids of gene expression
- Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy (Nature)
- Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma (Clinical Cancer Research)
- A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. (Journal of Clinical Oncology)
- Tenets of PTEN tumor suppression. (Cell)
- Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers (Nature Medicine)
- Exploration, normalization, and summaries of high density oligonucleotide array probe level data. (Biostatistics)
- Repeated observation of breast tumor subtypes in independent gene expression data sets (Proceedings of the National Academy of Sciences of the United States of America)
- Purification and unique properties of mammary epithelial stem cells (Nature)
- Generation of a functional mammary gland from a single stem cell (Nature)
Their papers
- BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. (2010) — 792 citations
- Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors (2009) — 674 citations